Praxis(US:PRAX) Financial Modeling Prep·2025-12-09 22:08Core Viewpoint - Praxis Precision Medicines has experienced significant stock performance improvements due to positive clinical trial results and analyst upgrades, indicating strong investor confidence in the company's future prospects [1][5]. Stock Performance - PRAX's stock has increased by 520% over the past three months, primarily driven by successful late-stage studies of ulixacaltamide for essential tremor treatment [2][5]. - The current stock price is $264.06, reflecting a slight decrease of 2.55% or $6.92 from previous levels [3][5]. - The stock has shown considerable volatility over the past year, with a high of $278.44 and a low of $26.70 [3]. Analyst Ratings - Jefferies upgraded PRAX's stock to a "Buy" rating, raising the price target from $300 to $450 [1][5]. Market Capitalization and Trading Volume - Praxis Precision Medicines has a market capitalization of approximately $5.58 billion, with a trading volume of 238,597 shares [4][5]. Clinical Development - The company's progress on pre-New Drug Application steps and positive data for relutrigine have contributed to the recent stock rally, with a regulatory filing anticipated in early 2026 [4].